Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 06, 2015 3:11 PM ET

Pharmaceuticals

Company Overview of ISTA Pharmaceuticals, Inc.

Company Overview

As of June 5, 2012, ISTA Pharmaceuticals, Inc. was acquired by Bausch & Lomb Incorporated. ISTA Pharmaceuticals, Inc. discovers, develops, and markets remedies for eye diseases and conditions in the United States. It offers products to treat eye allergies and diseases; and therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. The company’s marketed products comprise BROMDAY, a bromfenac ophthalmic solution for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extractions; BEPREVE, a bepotastine besilate ophthalmic solution for ocular itching associated with allergic conjunctivitis; ISTALOL...

50 Technology Drive

Irvine, CA 92618

United States

Founded in 1992

330 Employees

Phone:

949-788-6000

Fax:

949-788-6010

Key Executives for ISTA Pharmaceuticals, Inc.

ISTA Pharmaceuticals, Inc. does not have any Key Executives recorded.

ISTA Pharmaceuticals, Inc. Key Developments

Bausch + Lomb Announces Settlement with the U.S. Department of Justice to Resolve and Conclude ISTA Pharmaceuticals Inc

Bausch + Lomb announced has reached agreement with the U.S. government to resolve and conclude civil and criminal allegations against ISTA Pharmaceuticals Inc. The settlement involves conduct by ISTA that occurred between January 2006 and March 2011, well before Bausch + Lomb's acquisition. Bausch + Lomb was aware of the government investigation prior to its acquisition, and has fully cooperated with the government to resolve this matter. As part of the settlement, ISTA has agreed to pay approximately $34 million in civil and criminal fines including interest and attorney's fees, and will be prohibited from participating in federal healthcare programs such as Medicare and Medicaid. However, Bepreve(R), Bromday(R), Istalol(R), Prolensa(R) and Vitrase(R) have been transferred to Bausch & Lomb Incorporated, and therefore are not subject to any exclusion resulting from this settlement and continue to be eligible for reimbursement under those programs.

Similar Private Companies By Industry

Company Name Region
Cancer Prevention Pharmaceuticals, Inc. United States
Doctor's Natural Solutions Inc. United States
Bennu Pharmaceuticals Inc. United States
Pacira Pharmaceuticals, Inc., a California Corporation United States
Consensus Biolabs, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISTA Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.